Pancreatic Adenocarcinoma, Version 2.2014

Margaret A. Tempero, Mokenge P. Malafa, Stephen W. Behrman, Al B. Benson, Ephraim S. Casper, E. Gabriela Chiorean, Vincent Chung, Steven J. Cohen, Brian Czito, Anitra Engebretson, Mary Feng, William G. Hawkins, Joseph Herman, John P. Hoffman, Andrew Ko, Srinadh Komanduri, Albert Koong, Andrew M. Lowy, Wen Wee Ma, Nipun B. MerchantSean J. Mulvihill, Peter Muscarella, Eric K. Nakakura, Jorge Obando, Martha B. Pitman, Sushanth Reddy, Aaron R. Sasson, Sarah P. Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer L. Burns, Deborah A. Freedman-Cass

Research output: Contribution to journalReview articlepeer-review

309 Scopus citations

Abstract

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize major discussion points from the 2014 NCCN Pancreatic Adenocarcinoma Panel meeting. The panel discussion focused mainly on the management of borderline resectable and locally advanced disease. In particular, the panel discussed the definition of borderline resectable disease, role of neoadjuvant therapy in borderline disease, role of chemoradiation in locally advanced disease, and potential role of newer, more active chemotherapy regimens in both settings.

Original languageEnglish
Pages (from-to)1083-1093
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number8
DOIs
StatePublished - Aug 1 2014

Fingerprint

Dive into the research topics of 'Pancreatic Adenocarcinoma, Version 2.2014'. Together they form a unique fingerprint.

Cite this